Literature DB >> 9460951

Giant-cell tumour of bone metastasising to the lungs. A long-term follow-up.

K A Siebenrock1, K K Unni, M G Rock.   

Abstract

We reviewed 23 patients with a giant-cell tumour (GCT) of bone and histologically-proven lung metastases at a mean of 11.9 years (3 to 24.5) after the original diagnosis. The mean age of the patients at diagnosis was 27.3 years (9 to 61); the male to female ratio was 0.9:1. The most common primary site was the distal radius. The mean interval between the onset of the tumour and the detection of lung metastases was 4.1 years (0 to 24). There had been local recurrence in 19 (83%) either before or at the time of diagnosis of lung metastasis. Surgical resection alone was the preferred treatment for lung metastases in 70% and resulted in 18 patients (76%) being free from disease when last reviewed. One patient had the spontaneous regression of lung metastases and was free from recurrence 16 years later. Sixteen patients (69.7%) have survived and four (17.4%) have died from progression of the tumour. Three other deaths were not related to the tumour. Local recurrence and a primary lesion at the distal radius seem to be associated with an increased risk of lung metastases. Repeated surgical resection of lung metastases gave a high rate of survival.

Entities:  

Mesh:

Year:  1998        PMID: 9460951     DOI: 10.1302/0301-620x.80b1.7875

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  61 in total

1.  A novel approach to juxta-articular aggressive and recurrent giant cell tumours: resection arthrodesis using bone transport over an intramedullary nail.

Authors:  S Vidyadhara; Sharath K Rao
Journal:  Int Orthop       Date:  2006-05-25       Impact factor: 3.075

2.  Seven-year survival after intralesional resection and adjuvant radiotherapy for a giant-cell tumour of the sixth cervical vertebra.

Authors:  Bernard Rerri; Temilolu Opadele
Journal:  Can J Surg       Date:  2009-08       Impact factor: 2.089

Review 3.  Denosumab in the treatment of giant cell tumor of the spine. Preliminary report, review of the literature and protocol proposal.

Authors:  Stefano Boriani; Riccardo Cecchinato; Fabrizio Cuzzocrea; Stefano Bandiera; Marco Gambarotti; Alessandro Gasbarrini
Journal:  Eur Spine J       Date:  2019-05-16       Impact factor: 3.134

Review 4.  Giant cell tumor of bone: current treatment options.

Authors:  Keith M Skubitz
Journal:  Curr Treat Options Oncol       Date:  2014-09

5.  Denosumab does not decrease the risk of lung metastases from bone giant cell tumour.

Authors:  Shinji Tsukamoto; Andreas F Mavrogenis; Giulio Leone; Alberto Righi; Manabu Akahane; Piergiuseppe Tanzi; Akira Kido; Kanya Honoki; Yasuhito Tanaka; Davide Maria Donati; Costantino Errani
Journal:  Int Orthop       Date:  2018-08-11       Impact factor: 3.075

Review 6.  Integration of denosumab therapy in the management of giant cell tumors of bone.

Authors:  Daniel T Miles; Ryan T Voskuil; Wood Dale; Joel L Mayerson; Thomas J Scharschmidt
Journal:  J Orthop       Date:  2020-03-28

Review 7.  Giant-cell tumours of bone of the hand and wrist: a review of imaging findings and differential diagnoses.

Authors:  S L J James; A M Davies
Journal:  Eur Radiol       Date:  2005-05-03       Impact factor: 5.315

Review 8.  Giant-cell tumor of bone, anti-RANKL therapy.

Authors:  Armelle Dufresne; Olfa Derbel; Philippe Cassier; Gualter Vaz; Anne-Valérie Decouvelaere; Jean-Yves Blay
Journal:  Bonekey Rep       Date:  2012-09-05

9.  [Giant cell tumor of bone with rapid malignant course].

Authors:  M R Lachat; M Weber; M D Cserhati; H P Honegger; A R von Hochstetter
Journal:  Orthopade       Date:  2004-03       Impact factor: 1.087

10.  What role for radiobiphosphonates bone scintigraphy in the monitoring of an unusual bone giant cell tumor: a case report and literature review.

Authors:  Salah Nabih Oueriagli; Imad Ghfir; Hassna El Guerrouj; Nouzha Ben Raïs
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.